Inventor
VOSS MATTHEW E
SG27 patents
⚠️ This page may combine multiple inventors who share the name “VOSS MATTHEW E”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MERCK SHARP & DOHME
6 patentsUS9682978B2Jun 20, 2017
2,6,7 substituted purines as HDM2 inhibitors
MERCK SHARP & DOHME2 citations60
US9540377B2Jan 10, 2017
2,6,7,8 substituted purines as HDM2 inhibitors
MERCK SHARP & DOHME2 citations59
US8962611B2Feb 24, 2015
Substituted imidazopyridines as HDM2 inhibitors
MERCK SHARP & DOHME1 citations50
US8846657B2Sep 30, 2014
Substituted imidazopyridines as HDM2 inhibitors
MERCK SHARP & DOHME1 citations50
US9637493B2May 2, 2017
Substituted pyrrolopyrimidines as HDM2 inhibitors
MERCK SHARP & DOHME0 citations38
US9062071B2Jun 23, 2015
Substituted piperidines as HDM2 inhibitors
MERCK SHARP & DOHME0 citations37
DU PONT MERCK PHARMA
5 patentsUS5272269ADec 21, 1993
Disubstituted polycyclic systems and preparative methods therefor
DU PONT MERCK PHARMA10 citations68
US5414004AMay 9, 1995
Neurotransmitter releasers useful for cognition enhancement
DU PONT MERCK PHARMA2 citations62
US5308851AMay 3, 1994
Bispyridyl-containing heterocycles useful for treating cognitive disorders
DU PONT MERCK PHARMA2 citations62
US5424430AJun 13, 1995
Disubstituted polycyclic systems and preparative methods therefor
DU PONT MERCK PHARMA1 citations46
US5532247AJul 2, 1996
Neurotransmitter releasers useful for cognition enhancement
DU PONT MERCK PHARMA0 citations41
BRISTOL MYERS SQUIBB PHARMA CO
4 patentsUS6495565B2Dec 17, 2002
β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α
BRISTOL MYERS SQUIBB PHARMA CO50 citations91
US6984648B2Jan 10, 2006
Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α
BRISTOL MYERS SQUIBB PHARMA CO15 citations82
US6455522B1Sep 24, 2002
Cyclic sulfonamide derivatives as metalloproteinase inhibitors
BRISTOL MYERS SQUIBB PHARMA CO3 citations63
US6962938B2Nov 8, 2005
Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE)
BRISTOL MYERS SQUIBB PHARMA CO0 citations52